BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3133435)

  • 1. Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
    Nishida T; Nagasue N
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):635-9. PubMed ID: 3133435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma.
    Nishida T; Nagasue N; Kishi N; Imaishi K; Tateno N; Matsumura T; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1883-8. PubMed ID: 3209914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
    Nishida T; Nagasue N; Izumi S; Sakihama H; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):193-8. PubMed ID: 1690254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix.
    Nishida T; Nagasue N; Arimatsu T; Nagano H; Izumi S; Okura N; Matsumura T; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):590-4. PubMed ID: 2474043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer].
    Sawada M; Inagaki M; Hirota Y; Hongo J; Ozaki M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3091-4. PubMed ID: 3674894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
    Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.
    Girón CG; Ordónez A; Jalón JI; Barón MG
    Cancer Treat Rep; 1987 Sep; 71(9):851-3. PubMed ID: 3040245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH; Elias A
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
    Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European experience with ifosfamide in non-small cell lung cancer.
    Drings P
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.